Stock Events

Tandem Diabetes Care 

$44.12
56
+$0+0% Tuesday 16:58

Statistics

Day High
44.12
Day Low
43.77
52W High
44.12
52W Low
13.89
Volume
413
Avg. Volume
681
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

2MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-1.92
-1.3
-0.67
-0.05
Expected EPS
-0.76
Actual EPS
-0.65

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0M0F.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Dexcom
DXCM
Mkt Cap44.41B
Dexcom produces continuous glucose monitoring systems, directly competing in the diabetes management space with Tandem's insulin pumps.
Insulet
PODD
Mkt Cap13.66B
Insulet Corporation offers the Omnipod, an insulin management system that competes with Tandem's insulin pump products.
Medtronic
MDT
Mkt Cap101.91B
Medtronic is a major player in the diabetes care market, offering insulin pumps and continuous glucose monitoring systems that compete with Tandem's offerings.
Abbott Laboratories
ABT
Mkt Cap177.49B
Abbott Laboratories produces the FreeStyle Libre, a continuous glucose monitoring system, competing in the broader diabetes management market.
Senseonics
SENS
Mkt Cap247.39M
Senseonics Holdings offers the Eversense CGM system, a direct competitor in the continuous glucose monitoring market.
Thermo Fisher Scientific
TMO
Mkt Cap203.97B
Thermo Fisher Scientific, through its life sciences solutions, indirectly competes in the diabetes care market by providing technologies and supplies that support diabetes research and diagnostics.
Novo Nordisk
NVO
Mkt Cap445.94B
Novo Nordisk is a leading global healthcare company that, while primarily known for its diabetes medications, also invests in diabetes care devices and solutions, positioning it as a broader competitor.
Sanofi
SNY
Mkt Cap128.21B
Sanofi is involved in diabetes care through its insulin and glucose monitoring solutions, making it a competitor in the diabetes management space.
Baxter International
BAX
Mkt Cap18.01B
Baxter International offers medical devices that, while not directly competing in the insulin pump or CGM markets, provide various healthcare solutions that can be used in diabetes care.
Johnson & Johnson
JNJ
Mkt Cap372.29B
Johnson & Johnson, through its medical devices and pharmaceutical segments, has interests in the diabetes market, making it a broader competitor in the healthcare space for diabetes management.

About

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Show more...
CEO
Mr. John F. Sheridan
Employees
2000
Country
United States
ISIN
US8753722037
WKN
000A2H5BX

Listings